Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Licofelone (Merckle).

Changhai Ding1, Flavia Cicuttini

  • 1Menzies Centre for Population Health Research, University of Tasmania, Hobart 7000, Tasmania, Australia. changhai.ding@utas.edu.au

Idrugs : the Investigational Drugs Journal
|August 15, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bidirectional Relationship and Shared Mechanisms Between Sarcopenia and Osteoporosis: An Observational Study Integrating Genomic, Proteomic, and Metabolomic Data.

Aging cell·2026
Same author

Tristetraprolin protects against osteoarthritis by restraining chondrocyte mitochondrial DNA release through post-transcriptional regulation.

Journal of orthopaedic translation·2026
Same author

Temporal Trends and Cross-Country Inequalities in the Burden of Osteoarthritis, 1990-2021: Findings From the Global Burden of Disease Study 2021.

International journal of rheumatic diseases·2026
Same author

Corrigendum to 'Vitamins D and K jointly protect against osteoarthritis via regulating OSCAR during osteoclastogenesis' [J Orthop Transl <b>52</b> (2025) 387-403].

Journal of orthopaedic translation·2026
Same author

Associations of centrally acting analgesic use with total joint arthroplasty compared to selective serotonin reuptake inhibitor among osteoarthritis patients in a large prospective cohort.

BMC medicine·2026
Same author

Refining Osteoarthritis Risk Prediction: Average Sagittal Abdominal Diameter Complements and Enhances Body Mass Index With Sex-Specific Insights From National Health and Nutrition Examination Survey.

Health care science·2026
Same journal

Filibuvir, a non-nucleoside NS5B polymerase inhibitor for the potential oral treatment of chronic HCV infection.

IDrugs : the investigational drugs journal·2010
Same journal

Remimazolam, a short-acting GABA(A) receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures.

IDrugs : the investigational drugs journal·2010
Same journal

LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome.

IDrugs : the investigational drugs journal·2010
Same journal

Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis.

IDrugs : the investigational drugs journal·2010
Same journal

Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety.

IDrugs : the investigational drugs journal·2010
Same journal

Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.

IDrugs : the investigational drugs journal·2010
See all related articles

EuroAlliance is developing licofelone, a dual inhibitor targeting cyclooxygenase and 5-lipoxygenase. This compound shows potential for treating inflammatory conditions like osteoarthritis.

Area of Science:

  • Pharmacology
  • Drug Development

Background:

  • Inflammatory disorders represent a significant global health burden.
  • Osteoarthritis is a prevalent degenerative joint disease characterized by inflammation and pain.

Purpose of the Study:

  • To introduce licofelone, a novel dual inhibitor of cyclooxygenase (COX) and 5-lipoxygenase (5-LOX).
  • To highlight the potential therapeutic applications of licofelone in managing inflammatory conditions, with a focus on osteoarthritis.

Main Methods:

  • Development of licofelone by EuroAlliance, a consortium including Alfa Wassermann SpA, Lacer SA, and Merckle GmbH.
  • Characterization of licofelone as a dual inhibitor targeting key inflammatory pathways.

Main Results:

  • Licofelone effectively inhibits both cyclooxygenase and 5-lipoxygenase enzymes.

Related Experiment Videos

  • Demonstrated potential for treating inflammatory disorders.

    • Conclusions:

    • Licofelone represents a promising therapeutic candidate for inflammatory diseases.
    • Its dual inhibitory mechanism offers a novel approach to osteoarthritis management.